SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22% SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22%

MX1 Micro-X Limited

Healthcare · Medical Devices · website
$0.06
52wk 0.01 – 0.12
Overall
45.3
Value
76.6
Growth
36.6
Health
24.3
Quality
0.0
Momentum
88.5
Dividend
—
Price
About Micro-X Limited

Micro-X Limited engages in the design, development, manufacturing, and commercialization of imaging products for healthcare and security markets through cold cathode X-ray technology in the United States, the Asia-Pacific, Europe, the Middle East, and Africa. The company provides carbon nanotube-based X-ray products, including core X-ray tube and high-voltage generator components; and electronic switching hardware and reconstruction software products. It also provides Rover Plus for medical performance in a mobile system; Head CT, a standard ambulance or retrieval aircraft for stroke; Checkpoints, a modular passenger self-screening checkpoint for airports; Baggage scanner, a CT baggage scanner for passenger self-screening checkpoints; and imaging chains and custom X-ray imaging solutions, as well as engineering contract services and spare parts. The company has a strategic partnership with Billion Prima to develop and commercialize a baggage and parcel scanner product. Micro-X Limited was incorporated in 2011 and is based in Adelaide, Australia.

Price analytics

Returns

1 day -1.6%
1 week 37.8%
1 month 153.1%
3 months 72.2%
6 months 8.8%
1 year -41.0%
3 years -55.7%

Risk

Volatility (1y ann.) 112.4%
Beta vs ASX 200 1.18
Sharpe (1y) -0.01
VaR 95% (1-day) -8.3%
Max drawdown (1y) -87.8%
Off 1-year high -46.1%

Technicals

RSI(14) 79 OB
vs 50DMA 113.1%
vs 200DMA 18.6%
Trend Death cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown (2 Oct 2026)
Value 76.6
Trailing P/E
—
Forward P/E
100
PEG ratio
—
EV / EBITDA
100
Price / Book
0
Price / Sales
75
Growth 36.6
Revenue growth (1y)
0
Revenue CAGR (3y)
73
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health 24.3
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
0
Current ratio
31
Debt / Equity
38
Quality (Profitability & Cash Flow) 0.0
Return on equity
0
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income —
No meaningful dividend — pillar excluded from the overall score.
Momentum 88.5
6-month return vs ASX 200
100
Price vs 200-day average
100
Price vs 50-day average
100
Position in 52-week range
45

Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).

Score history
Key metrics
Market cap
$46.65M
P/E (trailing)
—
P/E (forward)
-15.50
EPS (trailing)
-0.01
Dividend yield
—
Payout ratio
0.0%
Beta
-0.63
EV / EBITDA
-2.83
Price / Book
8.86
ROE
-158.0%
Operating margin
-311.7%
Net margin
-65.5%
Total cash
$3.14M
Total debt
$6.48M
Current ratio
1.33
Debt / Equity
1.31
Free cash flow
$-7.18M
Avg volume
1.37M
Latest annual results (FY ending 30 Jun 2025)
  • Revenue$13.05M
  • Gross profit$10.32M
  • Operating income-$17.05M
  • Net income-$13.89M
  • Diluted EPS-0.02
  • Free cash flow-$8.69M
  • Net debt$3.29M
Sector peers (Healthcare)
TickerMkt cap P/EScore
CSL $84.15B — 54.3
RMD $45.86B 21.2 74.4
SIG $29.91B 43.3 55.6
FPH $21.64B 57.5 71.1
PME $16.34B 61.8 69.0
RHC $12.56B 40.0 40.2
SHL $9.12B 15.0 43.0
COH $8.20B 55.5 39.4